Italy-based MolMed SpA has become the seventh company to get a positive recommendation from the European regulator to market an advanced therapy medicinal product, a group that includes cell and gene therapies as well as tissue-engineered products. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Regulation & Policy
